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ABSTRACT 
There is a significant and urgent need for affordable, fast, and accurate pathogen 
detection methods in resource-limited settings. Currently, accurate pathogen detection methods 
are dependent upon special equipment or reagents, specialized training to operate such 
equipment, electricity or cold storage, or sterile environments not feasible outside of the 
laboratory. Here we present a functionalized cellulose paper device towards an autonomous 3-
dimensional microfluidics chip to detect bacterial pathogens. The microfluidic device utilizes a 
nucleic acid sandwich assay that detects the presence of bacterial RNA through complementary 
strand binding. An oligonucleotide “capture strand” immobilizes the targeted RNA sequence to 
the device, while a “detection strand” produces a visible colorimetric change due to gold 
nanoparticle conglomeration.  A smart phone application and camera quantifies the concentration 
of the bacterial RNA present in the sample. This detection method can determine concentrations 
in the lower limits of the femtomolar range. The microfluidic device was fabricated using wax 
printing on cellulose filter paper, which was then folded into a final 3-D configuration. The 
simplicity and specificity of this paper-based assay was verified by the detection of E. Coli target 
oligonucleotide.  
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CHAPTER 1: INTRODUCTION 
I. Problem Statement: The Need for ASSURED Bacterial Detection 
 
There is a real and urgent need for better detection methods for bacterial 
pathogens. In 2008, the World Health Organization (WHO) published a report stating that 
a tenth of the global health burden is caused by unsanitary water [1].  Included in this 
statistic are the estimated 3.4 million deaths that occur every year due to waterborne 
illnesses [1].  Too often, these deaths arise from inadequate preventative detection 
methods for bacterial pathogens. While many methods currently exist to detect these 
pathogens, they all fail to meet the WHO’s guidelines for low-cost and deliverable 
technologies that can be used on-site in remote locations.  These criteria, abbreviated 
ASSURED and listed in Table 1, outline the necessary characteristics of a feasible 
technology for use in resource-limited areas [2]. Those who live in resource-limited areas 
with minimal sanitation have the greatest need for an improved detection method, so any 
device that does not meet all of criteria outlined by the WHO is futile in this setting. We 
wish to address the alarming health concern of bacterial illnesses globally by developing 
an ASSURED device that can detect bacterial pathogens at the point of care in even the 
most remote locations.  Those living in at-risk areas will benefit from quicker and 
affordable detection of bacteria in water, food, or infections while World Health workers 
benefit from easier diagnosis and reduced costs for these tests. 
 
Table 1: ASSURED Criteria. World Health Organization’s ASSURED criteria for point of care devices in 
resource-limited areas. 
A S S U R E D 
Affordable Sensitive Specific User 
-Friendly 
Rapid 
and 
Robust 
Equipment-
Free 
Deliverable  
to End Users 
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CHAPTER 2: LIMITATIONS OF EXISTING TECHNOLOGIES 
I. Reliance upon External Equipment  
 
Currently, accurate pathogen detection methods are dependent upon special 
equipment or reagents, electricity or cold storage, or sterile environments not feasible 
outside of the laboratory. To address these limitations, devices using nucleic acids to 
detect specific gene targets have been implemented with great success; they are valid in a 
wide variety of applications, such as food and environmental monitoring and medical 
diagnostics. Methods of hybridizing target nucleic acids to complementary 
oligonucleotides have been studied extensively over the past several decades [3,4]. 
Nucleic acids are favorable biomarkers because they are specific and sensitive [5], stable 
over a wide range of temperatures [6], durable over time [6], and non-toxic. The 
advantages of nucleic acid biomarkers address many of the WHO’s ASSURED criteria 
including sensitivity, specificity, robustness, and deliverability to end users. Nucleic acids 
only bind to complementary strands of oligonucleotides, making the assay incredibly 
sensitive and specific for the detection of a chosen bacterial pathogen. A device intended 
for use in remote locations must be durable enough to withstand travel to the location 
without losing functionality along the way. Because nucleic acids are stable over a wide 
range of temperatures and durable over time, they are the ideal sensing platform to be 
used in a point-of-care device. 
II. Unsuitable Assay Substrates 
 
Oligonucleotide sandwich assays have been performed on numerous substrates 
such as glass [7], hydrogels [8], quantum dots [9], and carbon nanotubes [10]. While each 
biomaterial has its own advantages, toxicity and decreased specificity due to small 
surface area [11] hinder the implementation of these substrates in point-of-care devices. 
For this reason, we propose a paper-based device because cellulose has a high surface 
area and is inherently non-toxic [12]. Cellulose is comprised of numerous fibers, which 
allow oligonucleotides to bind to the cellulose in 3-dimensions, as opposed to only the 2-
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dimensional surface of other substrates [11]. The increased surface area enhances the 
overall sensitivity of the assay. Cellulose is fundamentally inert, but can be functionalized 
with zirconia, which has been shown to covalently link cellulose and oligonucleotides 
[11]. Gold nanoparticles (AuNPs) used in sandwich assays performed on zirconia-coated 
cellulose can still produce colorimetric results with high sensitivity [7, 13-14]. 
Additionally, cellulose is the most abundant natural polymer on earth [15], making it one 
of the cheapest biomaterials available for use in a medical device. This therefore meets 
the affordability criteria outlined by the WHO for a point-of-care device.  
III. Inadequate Analysis Methods 
 
Electrochemical [16], optical [17], and mass-sensitive methods [18] have been 
used to detect a binding event between oligonucleotides and the target sequence. While 
these methods are accurate and well established, they require additional equipment and 
training to operate. Such devices are not practical in resource-limited settings because 
laboratories are scarce, and the end-users who need a bacterial detection device may not 
know how to use them. Therefore, we move toward an autonomous microfluidic chip that 
uses a smartphone and application for analysis. Smart phones are becoming more and 
more prevalent in the developing world, and because of this scientists are looking to 
bridge the gap between patients and doctors by using smart phones as diagnostic tools 
[19]. The cell phone camera takes a picture of the colorimetrically altered substrate; the 
picture is then analyzed by a mobile application that can produce quantitative 
measurements that cannot be deduced by the naked eye alone [19]. The use of smart 
phones in medical diagnostics meet the equipment-free and user-friendly criteria given by 
the WHO. Because mobile phones are common and simple to use, patients can easily take 
charge of their own health, even in remote locations with limited access to trained 
professionals and laboratories. 
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CHAPTER 3: NOVEL DESIGN PROPOSAL 
I. Sandwich Assay Platform 
 
Our method of bacterial detection employs a sandwich assay using customized, 
single-stranded oligonucleotide sequences that are mimic to bacterial RNA sequences.  
Our “Capture” strand, named as such because it will “capture” the bacterial RNA 
sequence, is immobilized on cellulose functionalized with a thin, zirconia coating.  The 
Capture sequence is complementary to the known “Target” sequence of pathogen RNA. 
Therefore, the Target strand represents the specific bacterial RNA sequence of the 
pathogen we are detecting.  For the purposes of this device, we are using a known 
sequence unique to E. coli as our Target strand.  When the Target bacterial strand binds 
to the Capture strand, it is immobilized on the paper substrate. To detect a binding event 
between the Capture strand and the Target strand, a third oligonucleotide sequence, called 
the “Detection” strand, is then introduced to complete the sandwich assay.  The Detection 
DNA strand is conjugated with 20nm gold nanoparticles on the 3’ end of the sequence.  
When the detection strand binds to the immobilized Capture+Target complex, the 
conglomeration of gold nanoparticles produces a red color on the paper.  This 
colorimetric change can be difficult distinguish, as the red color is faint. Therefore, silver 
enhancement solution is then used to amplify the color change. In the presence of gold 
nanoparticles, silver enhancement solution will deposit solid, silver nanoparticles onto the 
gold nanoparticles. The papers then turn gray in color, with darkness varying upon the 
concentration of the Target strand. A schematic of this assay can be found in Figure 1.  
This assay is both sensitive and specific, detecting target concentrations well into the 
femtomolar range. 
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Figure 1: Sandwich Assay Design Schematic (1) Cellulose is coated with a thin film of zirconia. (2) 
Zirconia-coated cellulose immobilizes Capture DNA. (3) Target DNA binds to Capture DNA. (4) 
AuNP/Detection probe completes sandwich assay and (5) is enhanced with silver solution, producing 
colorimetric response. 
 
II. Integrated Platform in Microfluidic Chip 
 
 To create a WHO ASSURED device, the sandwich assay platform must be 
integrated into an autonomous, user-friendly microfluidic chip. On the lab bench, the 
different reagents are added sequentially by hand to produce the desired detection signal. 
However, this device is not intended for use in a lab with specialized lab equipment to 
carry out the reaction. Therefore, we must engineer a device to automatically carry out all 
steps of the sandwich assay so that the device is user friendly, even for an untrained end 
user.  
Our proposed microfluidic chip will use the fundamentals of paper origami to 
construct a 3-dimensional (3D) chip. As presented by Crooks et. al., this paper-folding 
technique to fabricate 3D microfluidic chips minimizes costs, and allows for simple and 
rapid assembly and unfolding for analysis [20]. The device will be fabricated onto a 
single piece of cellulose filter paper, and then folded into the final 3D shape.  When a 
fluid is introduced to the device, it will flow horizontally due to capillary action, and 
vertically due to gravitational force. To guide the fluid movement, hydrophobic regions 
and hydrophilic channels will be created. Before folding, we will be able to deposit and 
dry the various reagents of the sandwich assay into the channels. We intend to carry out 
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each step of the sandwich assay as the fluid moves from channel to channel, rehydrating 
the required assay reagents along the way. A schematic of our proposed chip can be 
found in Figure 2.    
  
 
Figure 2: 2-Dimensional View of Device. The orange layer represents the layer upon which the assay 
takes place. This layer is predeposited with zirconia+Capture oligonucleotide and will change color in the 
presence of the target strand. The 2 layers above the zirconia piece will contain the Detection strand that 
will anneal to the introduced Target strand and then be introduced to the zirconia paper. The layers below 
the orange piece will contain the reagents required to carry out silver enhancement to amplify the biosignal 
given off by the Detection strand.  
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 To fabricate our 3D chip, the proposed design of Figure 2 will be wax-printed 
onto cellulose filter paper. Wax printing is analogous to inkjet printing except that it 
utilizes solid ink blocks as opposed to liquid ink cartridges. The solid wax ink is 
hydrophobic, and will not smear when exposed to fluids. Using the ink’s innate 
hydrophobicity, we will be able to create hydrophilic channels in which the sample fluid 
will flow. As explored by Renault et. al., wax printing has several advantages over other 
fabrication methods; wax printing is incredibly fast, allowing hundreds of devices to be 
made in a short amount of time, therefore increasing the manufacturability of these 
devices [21]. Additionally, wax printing minimizes contamination of the channels 
through which fluid will flow, ultimately resulting in a more accurate and reliable device 
[21]. 
 The final component of our device will be a case to house the 3D paper substrate. 
Using Solidworks, a drawing will be created to be 3D-printed using the standard 
Makerbot plastic extruders. The layer upon which the full assay takes place is the third 
layer of our proposed design. Therefore, we must design a housing component that will 
not have to be taken apart entirely so that the paper can be unfolded to reveal the results 
on the third layer. To this end, we will design the third layer to land on a removable part 
so that it can be extracted for analysis without disturbing the entire column of layers. 
III. Analysis by Mobile Phone Application 
 
 Once the assay is completed and the critical zirconia layer has been removed from 
the vertical column, the colorimetric change must be analyzed. We are using a cell phone 
camera and mobile application to carry out the analysis because smart phones are 
becoming increasingly common in the developing world. The amount of bacteria in a 
sample will be quantified by taking a picture of the colorimetrically altered paper. The 
mobile phone will analyze the red, green, and blue (RGB) values of each pixel. This pixel 
analysis will ultimately produce a quantitative value related to the concentration of 
bacteria present in the sample. This mobile phone application gives the end-user the 
unique opportunity to take charge of their own health, even when professional medical 
resources are limited. This preventative care device has the potential to greatly reduce the 
disease states caused by unsanitary water. 
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CHAPTER 4: PROJECT PLANNING 
 
I. Team Management 
 
To bring this project to fruition, we will be working closely together to ensure that 
the work is done accurately and in a timely manner. Each team member will spend 
around 6 hours in the lab per week; this amount of time will be required to meet our 
proposed goals. During the lab time, both partners will work on both the bench top assay 
and integration into the microfluidic device. Both partners do not have to be in the lab at 
the same time, but will split the work evenly. For difficult or tricky procedures, both 
partners will work together to ensure each protocol is carried out accurately.  
Our team will be meeting weekly with our project advisor, Dr. Ashley Kim. 
During these meetings, results obtained on a weekly basis will be presented for review. 
This time will be used to make appropriate modifications and to answer any questions 
that may arise. Outside of our weekly meetings, we will communicate efficiently, 
ensuring that Dr. Kim is up to date on our progress. Additionally, meetings will be 
scheduled with Dr. Kim and other Santa Clara University faculty members who have 
expertise in a given topic. By utilizing these resources, we are more likely to create a 
viable and sustainable product.  
  
II. Proposed Timeline 
  
Table 2: Quarterly Goals. List of goals to complete on a quarterly basis. Note that work done in fall 2014 
must be validated before the winter and spring goals can be achieved.  
Quarter Goals 
Improve AuNP-Detection conjugation methods 
Determine viability of silver enhancement solution 
Test gold enhancement technique 
FALL 2014 
Research microfluidic chip fabrication methods 
Design microfluidic chip 
Begin wax printing devices  WINTER 2015 
Test fluid movement through wax-printed devices 
Validate DNA movement through device 
Dry assay reagents into channels to integrate 
sandwich assay into the device 
Test enhancement step on device  
Present at Senior Design Conference 
SPRING 2015 
Complete thesis.  
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III. Budget 
 
Table 3:  Budget. Outline of the expenses of this project. The source of funding is the Roelandt’s Grant, 
totally $3900.00 
Material Cost 
Oligonucleotide Sequences - $2000.00 
Xerox wax printer - $630.00 
Wax ink cartridges - $175.00 
Zirconium IV Butoxide - $300.00 
Gold Nanoparticles - $200.00 
Cellulose filter paper - $50.00 
Denhardt’s Solution - $130.00 
Conference Registration - $415.00 
Total Expenses - $3900.00 
Roelandt’s Grant + 3900.00 
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CHAPTER 5: PRELIMINARY RESULTS AND PROTOTYPING 
I. Benchtop Sandwich Assay Analyzed by Mobile Application 
 
 Before the final microfluidic prototype is made, the oligonucleotide sandwich 
assay needed to be validated on the benchtop to demonstrate the specificity and 
sensitivity of the detection platform. To this end, we performed the assay manually 
(methods described in chapter 8); in the final design, the manual steps will be integrated 
into the chip design so the end-user does not have to carry out any difficult protocols to 
produce the results. Ultimately, higher concentrations of the target strand (the 
complimentary bacterial DNA strand) will produce the darkest colorimetric change, 
while lower concentrations will produce a lighter colorimetric change. To test this theory, 
we introduced 1µM-10fM (5 100-fold dilutions and a control) of Target oligonucleotide 
to the immobilized zirconia+Capture complex, followed by incubation in the AuNP-
conjugated Detection strand. Therefore, a gradient of darkness should be visible to the 
naked eye, with 1µM paper being the darkest, 1fM paper being the lightest, and the 
control showing no color change. The color gradient produced by the assay can be found 
in Figure 3. 
 
 
Figure 3: Camera Phone Images of Completed Sandwich Assay. Images demonstrate the color gradient 
produced by varying concentrations of target oligonucleotide. 
 
 As seen in Figure 3, the color gradient was visible to the naked eye. However, a 
more quantitative analysis of the color change can be garnered using the mobile phone 
application. The mobile application is a replacement for a lab microscope, which can 
easily analyze colorimetric changes. We intend that this device will be used in a resource-
limited settings where traditional microscopes are unavailable. Therefore, we tested the 
validity of the mobile application in comparison to a lab microscope. 
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Figure 4: Microscope and Mobile Image Analysis. Microscope results shown in black and mobile app 
results shown in red. Both instruments produce comparable trend line. 
 
 From the data shown in Figure 4, the mobile phone application will serve as a reasonable 
analysis device for use in resource-limited settings. Relative intensity is a measure of how much 
light is present in a given image. Therefore, the lightest paper (the control) has the highest 
intensity and so on down to the 1µM concentration. The computer engineering team will 
continue to improve the mobile phone application so the trend line of the mobile phone 
more closely mimics that of the lab microscope. Given the results of the benchtop 
sandwich assay in conjugation with the mobile phone application analysis, we believe 
this platform can be successfully integrated into a 3D microfluidic chip.  
II. Microfluidic Chip Fabrication 
 
 Upon completion of the sandwich assay validation, we gathered the parts required 
to actually fabricate our device. We purchased a wax printer, and have been able to print 
our microfluidic chip. We have printed our device onto an 18cm diameter cellulose filter 
paper, cut out the unnecessary components, and folded the device into its 3D shape. We 
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have validated the guided fluid movement through the hydrophilic channels by using 
dyed water samples. The wax printer ink has proven its hydrophobicity as no traces of 
water can be seen in the hydrophobic spaces. 
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CHAPTER 6: EXPECTED RESULTS 
I. Sequential Assay Performed on Self-Contained Microfluidic Chip 
 
Upon validation of the assay platform and directed fluid movement through the 
3D wax printed microfluidic chip, we move to integrate the platform onto the chip itself. 
The platform can be split up into two distinct phases; the first phase contains the 
immobilization of the zirconia+Capture+Target+Detection complex. To do so, we will 
dry the various reagents of the assay onto the chip. Introduction of the fluid sample will 
rehydrate the reagents so the full assay can take place. In our final fabricated device, we 
intend to pre-load the critical zirconia paper with the Capture strand already immobilized, 
which will ultimately reduce the time required to complete the assay. Therefore, the 
Detection strand will be dried onto a channel, and then will be rehydrated upon 
introduction of the Target oligonucleotide. Once rehydrated, we anticipate that the 
Detection strand will be able to anneal freely to the target strand and the preloaded 
zirconia+Capture complex. Once immobilized onto the zirconia layer, the complex will 
be stable for the signal enhancement step.  
II. Signal Production and Enhancement on Microfluidic Chip 
 
 Once the zirconia+Capture+Target+Detection complex is immobilized, the 
biosignal caused by the gold nanoparticle conjugated to the Detection strand must be 
amplified so that analysis can be done using the smart phone application. The silver 
enhancement step (see Chapter 7 for methods) includes the mixing of two solutions 
before addition to the immobilized complex. Therefore, we will be drying the reagents of 
the silver enhancement procedure into the chip channels. We anticipate that these 
solutions will mix upon rehydration, and the guided channels will introduce the silver 
solution to the immobilized complex from the assay completed in phase one. We expect 
that the papers will have a colorimetric change based upon the concentration of the target 
strand introduced in phase one comparable to the results seen when the procedure is 
carried out on the benchtop (see Figure 3). 
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CHAPTER 7: BACKUP PLANS 
I. Silver Enhancement 
  
 In our early work benchtop work with the platform assay, we quickly learned that 
the silver enhancement step was not just a simple mixing to two solutions. The silver 
enhancing solutions are incredibly reactive, so the reaction step must be carried out with 
great precision. Although preventative measures are taken to limit false-positive results, 
we found that silver enhancing solution reacts with simple cellulose, and not gold 
nanoparticles exclusively. This is of grave concern for our device because it is entirely 
cellulose-based. Although we were able to produce clear results with this method, we had 
to carefully monitor the reaction time to gauge how long the papers should be exposed to 
the silver solution. However, an enhancement step that requires vigilant monitoring and 
some extent of scientific discretion may not suitable for a device intended for use by 
untrained user. Fu et. al. also experienced the inconsistencies of silver enhancement in his 
work with a 2D paper microfluidic chip. As an alternative, his research group utilized a 
gold enhancement solution for signal amplification [22]. Instead of the solution causing 
silver nanoparticles to precipitate onto gold nanoparticle probes, the gold enhancing 
solution causes gold nanoparticles to precipitate onto gold nanoparticle probes. Fu reports 
that the gold enhancement solution is much more sensitive and greatly reduces false 
positives. If we continue to experience complications with the silver enhancing solution, 
we could possible substitute it for gold enhancement solution.  
II. Nanoparticle Conjugation 
 
 When the Detection oligonucleotide is synthesized, it is made with a 3’ thiol 
modification. Once the thiol is reduced, the gold nanoparticles can be conjugated to the 
strand for use in the final component of the sandwich assay. This step has proven difficult 
because the 3’ thiol may be very reactive. Therefore, once reduced, the thiol may oxidize 
quickly with any exposure to oxygen. In our early research, we experienced many 
difficulties trying to conjugate the nanoparticles to the Detection strand, which could 
likely be caused by inert thiol due to oxidization. The biosignal-emitting Detection strand 
is integral to the completion of our device as we can do no testing or analysis without it. 
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Therefore, if we cannot successfully conjugate the nanoparticles to the Detection strand, 
we can have the Detection strand synthesized with a 3’ C3 fluorescein modification. This 
strand would be analogous to the nanoparticle-conjugated strand, but the biosignal can 
only be seen under a microscope and cannot be enhanced by silver or gold enhancing 
solutions. Although this is not an ideal substitution, it would allow us to track the 
movement of the various assay components through the microfluidic chip. Ideally, the 
fluorescein labeled Detection strand could move through the chip and ultimately 
immobilize on the zirconia layer; therefore, if the immobilization occurs, the zirconia 
layer should glow under the microscope. A device that requires a lab microscope for 
analysis is not suitable for use in a resource-limited setting, but it could at least validate 
that the assay itself will work on a microfluidic chip. 
III. On-Chip Enhancement - Proof of Concept 
 
 If the detection strand cannot be successfully conjugated with gold nanoparticles 
consistently, we will be unable to determine if silver or gold enhancement can occur on a 
paper microfluidic chip; the enhancing solution is unable to deposit silver precipitates 
onto a C3 fluorescein modification. Until the conjugation step is perfected, we could still 
test the viability of on-chip signal enhancement. In this case, we will spot nanoparticles 
onto a zirconia-coated cellulose paper and let it dry. We would then deposit and dry the 
various solutions required for the enhancement into the channels of the microfluidic chip. 
Upon rehydration with water, we expect the reagents will all mix appropriately to 
precipitate the silver nanoparticles onto the dried gold nanoparticles. We would vary the 
concentrations of gold nanoparticles dried onto the zirconia layer in hopes of seeing a 
clear grayscale gradient much like the results we saw in the benchtop assay (see figure 3). 
The enhancement step is vital to produce a signal that can be analyzed by the mobile 
application; this step can still be validated by these methods even if we cannot 
successfully conjugate gold nanoparticles to the detection oligonucleotide. 
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CHAPTER 8: MATERIALS AND METHODS 
I. Materials 
 
 Oligonucleotides used in the testing and validation of the sandwich assay were 
obtained from Elim Biopharmaceuticals Inc (Hayward, CA).  Gold nanoparticles that 
were later conjugated to the Detection oligonucleotides were purchased from Sigma-
Aldrich, Inc (St. Louis, MI).  The zirconia utilized to functionalize the cellulose paper for 
DNA binding was obtained from Sigma-Aldrich, Inc (St. Louis, MI). Denhardt’s 
Solution, a component of the non-specific binding buffer, was also obtained from 
Invitrogen (Grand Island, NY).  Dithiothreitol (DTT), which was used to reduce the thiol 
on the 3’ end of the Detection oligonucleotide, was purchased from Sigma Aldrich, Inc 
(St. Louis, MI).  The silver enhancement kit used to amplify the AuNP biosignal was 
obtained from Sigma-Aldrich, Inc (Saint Louis, MI).  Salmon sperm DNA, another 
component of the non-specific binding buffer, was obtained from Thermo Fisher 
Scientific (Santa Clara, CA). The gold enhancement kit, used to amplify the AuNP 
biosignal, was obtained from Nanoprobes Inc (Yaphank, NY).  Concentrations of 
oligonucleotide solutions were determined using the NanoDrop UV-Vis Spectroscopy 
(Wilmington, DE).  Fluorescent imaging was conducted using the Olympus BX51WI 
epifluorescent microscope, and QCapture Pro6.0 software was used to characterize the 
fluorescence of the samples.  
II. Benchtop Sandwich Assay Validation 
a. Deposition of Zirconia 
 
 Zirconia was cyclically deposited onto cellulose filter paper as described by Xioa 
and Huang [23]. In summary, filter paper was placed into a pump-powered filtration 
apparatus. To begin the first cycle, the filter paper was washed thoroughly with ethanol. 
Then, 10mL of zirconia were added to the filtration funnel. The zirconia was left standing 
for 5 minutes, and then pulled through the filter for 3 minutes. The paper was then 
washed and filtered with sufficient water, which washes away any unreacted zirconia. To 
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complete the cycle, the paper was washed thoroughly with ethanol. This 5-step cycle was 
repeated 10 times to obtain a thin but visible layer of zirconia on the filter paper.  
b. Immobilization of Capture Oligonucleotide 
 
The Capture oligonucleotide was then bound to the cellulose+zirconia substrate at 
the 5’ terminus through a 24-hour submersion of the cellulose+zirconia substrate in the 
oligonucleotide.  Capture strands tagged with C3-Fluorescein at the 3’ terminus were 
synthesized with a fluorophore modification. The binding of the Capture+tag strands to 
the substrate was then visualized using fluorescent microscopy to determine the optimal 
concentration of capture bound to the paper. Zirconia+cellulose substrates were then 
incubated with untagged, optimal concentration capture strands for 24 hours, washed 
with water, and then air dried.  To prevent nonspecific binding to the cellulose+zirconia 
substrate, the cellulose+zirconia+Capture complex was bathed in a pre-hybridization 
solution (Denhardt’s solution, 0.1M salmon sperm DNA). The substrates were then 
washed in 10mM, 1mM Tris-EDTA buffer and air dried [23]. 
c. Immobilization of Target Oligonucleotide onto Zirconia+Capture 
Complex 
 
Target oligonucleotides were introduced at varying concentrations to the 
cellulose+zirconia+Capture substrates.  Target sequences tagged with a CAL Flour Red 
610 modification at the 5’ terminus were imaged to verify the binding to the substrate 
using fluorescent microscopy. The lower limit of detection of the target was determined 
[23]. Once the limit of detection was determined, untagged Target oligonucleotide was 
introduced to zirconia+Capture complex in varying concentrations ranging from 1µM to 
10fM. The zirconia+Capture complex was incubated with the target strand for 24 hours 
and then washed with water and air dried. 
d. Detection Nanoparticle Conjugation 
 
 The Detection oligonucleotide was synthesized with 3’ thiol modification to allow 
for gold nanoparticle conjugation. The dried Detection probe was resuspended in at 
100mM DTT solution for 1 hour. The Detection strand was then purified through G25 
columns. Gold nanoparticles were prepared by centrifugation at 13,200 rpm for twenty 
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minutes. The supernatant fluid was removed, and the nanoparticles were incubated with 
dATP in a ratio of 1000:1 dATP:AuNP for 15 minutes. The purified detection was then 
added to the dATP/AuNP mixture in a ratio of 1:500 AuNP/dATP:detection 
oligonucleotide. The probes were then left on a shaker at 60℃ for three hours, and then 
left to incubate on the benchtop for 2 hours at room temperature. After incubation, the 
probes were centrifuged and washed with 100mM phosphate buffer at pH 8.5. This wash 
step was repeated 3 times, and the probe was stored in 100µL of 0.3M NaCl, 10mM PBS 
with pH 8.0 at 4℃ [24]. 
e. Introduction of Detection Sequence 
 
 The gold nanoparticle conjugated Detection probe was then incubated with the 
zirconia+Capture+Target complex at 2µM for 90 minutes. The papers were then washed 
with water and bathed in 0.5M EDTA at pH 4.5 to prevent nonspecific signal 
enhancement. They were then washed with water again and left out to dry for 30 minutes.  
f. Signal Enhancement 
 
The silver enhancement solution was prepared by mixing equal volumes of 
Solution A and Solution B. The papers with the zirconia+Capture+Target+Detection 
complex were then incubated in the mixed solution for approximately 8 minutes followed 
immediate by a bath in Silver Stabilizer Solution. Finally, the papers were washed with 
water and dried for analysis. 
g. Assay Analysis under Microscope and Mobile Application 
 
 To quantitatively analyze the colorimetric signal produced in the enhancement 
step, papers were visualized under a fluorescent microscopy. Using ImageJ software, the 
relative intensity of the color was measured. A smart phone with an attachable 
microscope piece took pictures of each paper, and also produced the relative color 
intensity. The values given by the software and mobile phone application were compared 
to validate the mobile phone application. 
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III. Microfluidic Chip Fabrication 
a. Chip Design, Printing, and Heating 
 
 The microfluidic chip was designed using Microsoft Powerpoint. Once the image 
was made, it was wax printed onto 18 cm filter paper. The filter paper was then heated on 
a hot plate at 100℃ for approximately 8 minutes to allow the wax to melt into the 
cellulose. The unnecessary filter paper was cut away and the device was folded into its 
3D shape. 
IV. Integrating Sandwich Assay with Microfluidic Chip 
a. Determining Time Constraints and Volume Requirements 
 
 To transition the sandwich assay into the device itself, the time required for 
incubation and the volume of fluid required to run through the device must be 
determined. To this end, various volumes of colored fluid were introduced to the device 
to determine the minimum volume needed to reach the inner detection layer of the 
device. After this volume was determined, the time it took for the minimum volume to 
reach the detection layer was recorded.  
b. Validation of DNA Movement through the Device 
 
 For the proposed device design to function properly, the oligonucleotides must be 
able to move through the device. The oligonucleotides are carried in the fluid horizontally 
due to capillary action, and vertically through gravitational force. A small zirconia-coated 
cellulose strip (~4mm x 4mm) with immobilized Capture oligonucleotide (see chapter 
7.II.B for methods) was placed onto the detection pad. The required layers of the device 
were folded on top of the critical detection layer. Small weights that did not interfere with 
the device channels were laid atop the 3D device to compress the various layers of the 
device and to stabilize the zirconia+Capture substrate in its position. Following 
stabilization, 40µL of varying Target+tag oligonucleotide sequences were pipetted into 
the first channel of the device. The devices were left to incubate overnight 
(approximately 17 hours). After incubation, the zirconia+Capture+Target+tag papers 
were washed thoroughly with water and left to dry. Once the papers were dry, they were 
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analyzed using the fluorescent microscopy and ImageJ software. The device itself was 
also viewed under fluorescent microscopy to further view how the fluorescent 
oligonucleotides traveled through the device layers. 
 Once the oligonucleotide movement through the device was validated using 
fluorescently tagged oligonucleotides, the above procedure was repeated. However, 
untagged Target oligonucleotides were introduced to the first channel as opposed to the 
Target+tag sequences. After incubation, the papers were washed with sufficient water 
and bathed in EDTA to prevent non-specific binding. The papers were then incubated in 
2µM Detection oligonucleotide for 90 minutes. Following incubation, the papers were 
washed with water and placed into gold enhancement solution for 2 hours. After the 
enhancement step, the papers were washed with water and left to dry. When papers were 
dry, the colorimetric change was analyzed using fluorescent microscopy and ImageJ 
software. 
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CHAPTER 9: RESULTS 
 
I. Capture+Tag Verification 
 
 
 
 
Figure 5: Capture+Tag Fluorescent Images. Fluorescent images taken of cellulose+zirconia papers with 
immobilized Capture+Tag oligonucleotides. Based on qualitative analysis, the brightness of the 
fluorescence increases as the Capture oligonucleotide concentration increases. 
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Figure 6: Capture+Tag Image Analysis. Numerical analysis of fluorescence brightness garnered from the 
fluorescent microscope and ImageJ software. This quantitative analysis demonstrates that the fluorescent 
intensity increases with increasing Capture+Tag oligonucleotide concentration. The 7.5µM and 15µM 
concentrations have similar intensities, suggesting the papers become saturated with oligonucleotide in this 
region.  
 
II. Target+Tag Verification  
 
Figure 7: Target+Tag Fluorescent Images. Oligonucleotides were added at varying concentrations to 
zirconia+Capture strands. From qualitative observation, the brightness of the fluorescence increases with 
increasing Target+Tag oligonucleotide concentration.  
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III. Gold Enhancement Verification 
 
 
Figure 8: Completed Sandwich Assay. Quantitative measure of the darkness of 
zirconia+Capture+Target+Detection paper substrates after soaking in gold enhancement solution. Gold 
enhancement solution increases the effective radius of the gold nanoparticles conjugated to the Detection 
strand, changing the paper color from red to purple. As the Target oligonucleotide concentration increases, 
the papers become darker, therefore decreasing the relative intensity. 
 
IV. Target+Tag Movement through Device Demonstration 
 
Figure 9: DNA Flow through Device. Fluorescent Target+Tag DNA was passed through the device to 
land on zirconia+capture paper substrates. A) Fluorescent image of zirconia+Capture substrate to which no 
Target+Tag DNA was introduced through the device, therefore yielding minimal fluorescence. B) 
Fluorescent image of zirconia+Capture substrate to which 5µM Target+Tag DNA was introduced through 
the device, ultimately producing a fluorescent signal. C) Image of one channel of the microfluidic device, 
showing that the fluorescent DNA moves through the device channels. D) Image of a second channel of the 
device, also demonstrating the movement of DNA through the device. 
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V. Target Movement through device Followed by Detection-AuNP 
incubation and Gold Enhancement 
 
 
 
Figure 10: Completed Sandwich Assay after DNA Flow through Device Images and quantitative 
analysis of Target DNA ran through the device to land on zirconia+Capture paper substrate. Following 
incubation, the papers were washed and incubated with the Detection probe. The papers were then washing 
and bathed in gold enhancement solution. The images and numerical data show that darkness of the paper 
increases with increasing Target oligonucleotide concentration.  
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CHAPTER 10: DISCUSSION 
I. Assay Platform 
a. Capture+Tag Validation 
 
 In our final device proposal, we intended to manufacture the zirconia-coated 
detection layer with the Capture strand immobilized onto it. With this initial step done in 
the manufacturing process, the Capture strand is prepared to anneal to the target bacterial 
RNA as soon as it is introduced. Therefore, we needed to determine an optimal 
concentration of Capture oligonucleotide to immobilize onto the zirconia-coated 
cellulose. To determine this concentration, we incubated the zirconia-coated papers with 
varying concentrations of Capture+Tag oligonucleotides. The 5’ phosphate groups 
covalently bonded to the positively charged zirconia surface. The 3’ end was modified 
with C3 Fluorescein, which fluoresces a bright green color. In these trials, the 3’ end is 
not bound to any other substrates so the fluorescence can be easily analyzed.  
 In Figure 6, the images appear to fluoresce with more intensity as the 
concentration of Capture+Tag increases. Because the papers have a limited surface area, 
there is a limited concentration of Capture that can be bound to them. We aimed to 
determine an ideal Capture concentration that was larger that the upper limit of the RNA 
we would be testing in the second assay step (1µM), but was small enough to produce 
consistent results without wasting materials in manufacturing. In Figure 6, the 
fluorescence of the 7.5 µM and 15 µM Capture concentrations were comparable. 
Therefore, we determined that we would load the zirconia-coated cellulose papers with 
10 µM of Capture DNA for all future testing. 10 µM is well above our upper limit of 
detection, meaning there is enough Capture strands bound to the paper to immobilize the 
largest concentration of Target oligonucleotide we planned to test in the second step of 
the assay.  
b. Target+Tag Validation 
 
 To validate the second step of the sandwich assay, the Target oligonucleotide 
strands were synthesized with a 5’ CAL RED 610 modification. We hypothesized that the 
3’ end of the oligonucleotide would anneal to the complementary Capture strand already 
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immobilized on the zirconia-coated cellulose substrate. Therefore, the 3’ end containing 
the fluorescent modification would be unbound to any other substrates, allowing us to 
analyze the fluorescence accurately. We anticipated that the brightness of the fluorescent 
images would increase with increasing concentration of Target oligonucleotide. As seen 
in Figure 6, the 10 fM concentration fluoresces the least, and the brightness intensifies 
leading up to the 1 µM concentration.  
 To quantitatively analyze the fluorescent intensity, the fluorescent microscope and 
ImageJ software was used to produce numerical values of the intensity. Our qualitative 
analysis was affirmed with the quantitative data seen in Figure 7; the relative intensity, 
which is the measure of brightness in an image, increases with increasing concentrations 
of Target oligonucleotide.  
 Demonstrating a fluorescent gradient was a critical step in our research. 
Ultimately, we not only wanted our device to detect the presence of bacterial RNA in a 
sample, but we wanted to determine to what degree the bacteria is present. This step 
demonstrated that the assay was sensitive enough to distinguish one Target strand 
concentration from another.  
c. Gold Enhancement Validation 
 
 In a resource-limited settings, fluorescent microscopes are unavailable to use for 
the detection of bacterial pathogens. Therefore, the third strand of the sandwich assay 
was synthesized to create an optical signal when a binding event occurred between the 
Capture and Target strands. The Detection strand binds to the Capture+Target complex 
on its 5’ end, leaving the 3’ end conjugated with gold nanoparticle free. The signal 
produced by the nanoparticles alone is not strong enough to been seen and analyzed by 
the naked eye. Therefore, the papers are soaked in gold enhancement solution to darken 
the original signal. We anticipated that the gold enhancement step would produce a 
gradient similar to the gradient obtained by the fluorescent microscopy. As seen in Figure 
8, the papers become darker with increasing concentration of Target oligonucleotide. 
This therefore confirms that the Detection strand conjugated with gold nanoparticles can 
accurately detect varying concentrations of Target oligonucleotide present in a sample.  
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 In our original design proposal and preliminary results, we were using silver 
enhancement solution as opposed to gold enhancement solution. We quickly learned that 
the silver enhancement solution is highly reactive. The silver did not react with gold 
nanoparticles exclusively, as the silver would precipitate onto control groups that 
contained no gold nanoparticles. After producing many false-positives, we switched our 
signal amplification method to gold enhancement. Gold enhancement works similarly to 
silver enhancement; instead of precipitating silver particles onto the gold nanoparticles 
conjugated to the Detection strand, the solution precipitates gold nanoparticles. The gold 
nanoparticles we conjugate to the detection strand have a 20 nm diameter and are red in 
color. As the radius of the gold nanoparticles increases, the color changes to purple and to 
blue. When the gold enhancement solution precipitates gold nanoparticles onto the 
existing gold nanoparticles, the effective radius of the original probes increases. 
Therefore, the darkest colorimetric change caused by high Target oligonucleotide 
concentrations appears purple. In our testing, we have seen that gold enhancement 
solution significantly decreases the chance of producing false positives and the solutions 
are more selectively reactive. 
II. Chip Fabrication 
 
 Fabricating our device using wax printing is incredibly simple, therefore 
increasing the manufacturability of our product. The cellulose filter paper can be fed into 
the printer directly, allowing us to make dozens of devices within an hour. The printer 
only patterns the design onto one side of the filter paper, so the wax must be melted 
through the paper and on to the other side. To do this, we placed the patterned filter paper 
onto a hot plate, face up. The melting process must be monitored vigilantly because the 
wax does run when heated. Therefore, we saw that the widith of the channels would 
decrease, and sometimes completely close off if the paper is left on the hot plate too long. 
After fabricating many devices, the average device takes about 8-10 minutes to melt the 
wax onto the reverse side of the filter paper at 100℃ without closing the channels.  
III. On-Chip Assay and Enhancement 
a. Target+Tag Movement through Device 
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 The assay steps involving fluorescent analysis and gold enhancement have all 
been done on the bench top in our lab. However, this device is intended for use in the 
developing world, so the assay must be integrated into the device itself in order for our 
methods to be valid in a resource limited setting. The first step to integrating the assay 
was to demonstrate that the oligonucleotide strands could travel through the device layers 
to land on the detection layer containing the Capture strand immobilized on the zirconia-
coated cellulose. To show the movement of DNA through the device, we ran the 
Target+Tag oligonucleotide through two channels leading to a small piece of 
zirconia+Capture paper placed into the detection layer. Because this step was a proof of 
concept, we first ran fluid containing no Target DNA through the device as seen in Figure 
9A. We then ran a 40µL of 5 µM Target oligonucleotide through the device as seen in 
Figure 9B. After the incubation time, the paper was washed with water, dried, and viewed 
under the fluorescent microscope. By comparing Figure 9A and 9B, we have shown that 
oligonucleotides will move travel both horizontally through channels and vertically onto 
subsequent layers.  
 Figure 9C and 9D show the two channels the Target+Tag strand traveled through. 
Both of these images show some degree of fluorescence, indicating that there is 
Target+Tag DNA remaining in the channels. The channels were not washed before 
imaging so that we could verify that the DNA did in fact travel through every portion of 
each channel.  
b. Target Movement through Device Followed by Benchtop Detection 
Incubation and Gold Enhancement 
 After demonstrating the movement of DNA through the device, we aimed to 
produce a colorimetric gradient visible to the naked eye using varying concentrations of 
Target oligonucleotide to run through the device. Following incubation with the Target 
oligonucleotides, the zirconia+Capture+Target paper substrates were removed from the 
detection layer. They were incubated with the third Detection sequence, and were then 
incubated in gold enhancement solution. As seen in Figure 10, a gradient can be seen 
qualitatively and is affirmed by the quantitative analysis by the microscope. This step 
further verified that the assay is sensitive enough to detect varying concentrations of the 
Target DNA even when it is run through the device as opposed to incubating on the 
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benchtop. We did notice that the gold enhancement reaction took a great while to produce 
gold precipitates to change the color of the papers. Typically, this reaction takes minutes 
but this step took about 2 hours to complete. The control in this trial was not entirely 
white, suggesting that the enhancement solution has non-specifically precipitated gold 
nanoparticles that were not removed in the wash steps. Even though the control turned 
color slightly, it was still lighter than the lowest concentration we tested for (Figure 10).  
 In this step, we chose to use higher concentrations of Target DNA than usual 
because we were uncertain of how much Target DNA was going to be lost while moving 
through the channels. On the benchtop, we have shown that the assay can detect into the 
femtomolar range. Future work on this device will work to achieve the same sensitivity 
through the device as there is on the benchtop.    
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CHAPTER 11: PROJECT SUMMARY 
 
I. Objectives and Milestones 
a. Project Scope 
Our research demonstrates important advances in the long-term scope of this 
project.  Our role focused on validating the nucleic acid assay, improving the 
enhancement steps, and developing a prototype for the microfluidic device. 
We began working on this project in 2014.  At this time, nobody had been 
working on this research at Santa Clara for about a year.  Therefore, our initial stages of 
research involved restarting the research.  Table 4 shows the overall scope of the project 
and our role in it (shown in bold). 
 
Table 4: Project Timeline and Scope. Our contributions are bolded. 
Project Task Timeline 
Project Inception 2012 
Preliminary Research 2012 
Initial Assay Testing & Validation 2012 & 2014 
Assay Refinement 2014 
Device Fabrication 2015 
Device Integration 2015-Future 
Field Testing Future 
Project Completion Future 
 
b. Objectives 
 Our initial objective for this project was to have a functioning prototype of the 
microfluidic device.  Quickly, we realized that this projection was overly ambitious, and 
we adjusted our objectives to reach attainable milestones. Table 5 shows our completed 
and uncompleted milestones in this project. 
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Table 5: Project Milestones 
Milestone Date Completed 
Verify Capture Binding July 2014 
Verify Target Binding July 2014 
Conjugate DNA with AuNP August 2014* 
Verify completed sandwich assay August 2014* 
Design microfluidic device January 2015 
Test fluid flow on microfluidic device April 2015 
Verify DNA flow through device layers May 2015 
Test dried reagents on device May 2015 
Develop on-device lysis method Future 
Test device with bacterial cells Future 
Field test device for constraints Future 
*  DNA/AuNP conjugation was not reproducible until February 2015 
 
II. Design Evaluation   
a. Positives 
The microfluidic device that we have produced has numerous positive attributes 
that make it a promising avenue for future work.  It is design to detect bacterial 
pathogens, and we have demonstrated that it can accomplish this task.  Through both 
fluorescent imaging and colorimetric change, we have verified sensitive nucleic acid 
binding that corresponds to known bacterial RNA sequences.  
 Not only does the design detect bacterial pathogens, it does so while meeting most 
of the ASSURED criteria for a diagnostic device.  Our current prototype costs around $3 
or $4 dollars, making it affordable.  The nucleic acid assay is both sensitive and specific.  
The design of the device is user-friendly because it requires minimal sample-loading and 
easy to interpret results.  The device is also equipment free, as it can be used with or 
without a mobile phone.  All these aspects of the device make it deliverable to the end 
user.   
b. Negatives 
One challenge that has been associated with this device has been producing 
consistently reliable results.  Occasionally, the gold nanoparticles will color the control 
paper, confounding the results.  This issue with the design has been mitigated with 
control steps, such as rinsing the papers with EDTA to further prevent non-specific 
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binding.  Gold enhancement has also improved the consistency of the results, as opposed 
to previous methods which used silver enhancement instead.  This issue of reliability is a 
challenge in the design, but one that can be addressed with further testing and 
optimization of reagent concentrations. 
III. Future Work 
a. Assay Reproducibility 
 
 The sandwich assay is the fundamental platform of the device, and therefore must 
produce accurate results from trial to trial. In the early stages of our research, we had 
difficulty reproducing results from trial to trial. Through fluorescent microscopy, we 
were able to see that the Capture and Target strands were binding to their respective 
locations properly. The issues usually arose in the conjugation of gold nanoparticles to 
the Detection oligonucleotide. Without properly conjugated nanoparticles, the Detection 
strand cannot accurately detect the binding event between the Capture and Target strands. 
After much discussion with Dr. Korin Wheeler of the biochemistry department, we 
pinpointed the error we were making in the conjugate synthesis. The thiol on the 3’ end 
of the Detection strand will oxidize quickly after the initial reduction protocol. Therefore, 
the nanoparticles must be added to the reduced Detection strand immediately to force the 
reduced thiol to bind to the nanoparticles as opposed to oxidizing again. Towards the end 
of our project, we were able to make suitable AuNP-Detection conjugates that accurately 
detected the binding event between the Capture and Target sequences. The next team of 
researchers who picks up this project will need to verify our results by synthesizing more 
conjugates that produce a clear, colorimetric gradient when varying concentrations of 
Target oligonucleotide are added to the zirconia+Capture paper substrates.  
b. Dried DNA/AuNP on device 
Because we have been able to demonstrate that DNA will move through the 
device, the next step in integrating the assay into the device is to dry the AuNP-Detection 
conjugates into the device channels. The AuNP-Detection strand can be dried in the 
channel right before the detection layer. When the Target oligonucleotide is introduced to 
the device, we anticipate that the fluid will rehydrate the dried Detection strand. Ideally, 
the AuNP-Detection strand will anneal to the Target oligonucleotide within this device 
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channels, and ultimately travel to the detection layer containing the zirconia+Capture 
paper substrate.  
c. Bacterial Lysis on Device 
The focus of our research was on the development of the nucleic acid assay and 
device manufacturing.  This focus meant that we wanted to be as exact as possible in 
verifying the binding events for each stage of the assay.  Therefore, instead of using RNA 
from lysed bacterial cells, we used synthesized oligonucleotide sequences that were 
mimetic of the in vivo RNA.  Approaching the project in this way meant better control 
over our design experiments, but also meant that our research did not exactly simulate the 
conditions in which the device will be used.  
Since we used synthesized sequences for the Target bacterial strand, we did not 
need to use bacterial cells during our research, which by extension meant that we did not 
need to lyse bacterial cells.  In future work, bacterial cell lysis will be an important step 
in device use.  We anticipate that a lysis step will be integrated into our device, and will 
probably be the first stage of the device reactions.  Current literature in cell lysis suggests 
that chemical methods may be a viable solution.  Depositing detergents, such as SDS, on 
the device during production may be able to lyse the samples sufficiently to expose the 
RNA to the external environment.  Further research will be required to determine which 
chemicals to use, how much, and how they may affect subsequent reactions and DNA 
binding. 
d. Gold Enhancement on Device 
We have demonstrated that gold enhancement of gold nanoparticles is a reliable 
method of signal clarification for our device.  This method requires the combination of 
four different solutions – two combined for five minutes, followed by subsequent serial 
addition of the following two solutions – in equal volumes. While this is simple to 
perform in a lab, the conversion of such protocol to a device requires more attention.  
Tests need to be performed that the reagents can be dried on the paper and successfully 
rehydrated while retaining functionality.  Furthermore, the concentrations of the solutions 
may need adjustment to account for material lost while the volumes run through the 
device; earlier reactions steps need to travel farther than later steps, so higher 
concentrations will likely be needed to account for the loss.  Our current design includes 
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prototypical designs for the fluid flow of the gold enhancement solutions, but further 
testing will be required to optimize the reaction timing and concentration balances. 
e. Assay Validation with Bacterial RNA 
As mentioned in the “Bacterial Lysis on Device” section, we have been using synthesized 
DNA sequences to emulate the bacterial RNA which we will actually be testing for in 
real life applications.  Therefore, future work will require that bacteria cells be cultured 
and RNA be extracted.  Once the RNA is isolated from the bacterial cells, the sandwich 
assay will need to be tested using this RNA, as opposed to the sequenced Target strands 
which we have used thus far. 
f. Field Testing 
Once all the reaction steps have been transferred to the device and reliable results 
have been generated, field testing will be required to determine the practicality and 
constraints to the device.  Important factors, such as the shelf life, temperature range, 
humidity conditions, and numerous other environmental factors must be tested before the 
devices can be considered practical for field use.  Since an important aspect of our device 
design is to make it meet ASSURED criteria, comprehensive field testing will be vital to 
optimize the device. 
IV. Design Validity 
The principles upon which our design is based are well-established.  Paper-based 
microfluidics is an established field.  Nucleic acid reactions are thoroughly categorized 
and validated as sensitive and specific detection methods.  Our design repurposes these 
well-defined fields in a novel way that promises to be a valid approach to a serious global 
health issue.  At this stage in our research, we have no reason to believe that the design is 
invalid. 
V. Design Constraints 
Our project has many strengths in the design that make it adaptable and applicable in 
numerous settings; however, there are certain limiting factors that are associated with the 
inherent characteristics of our device design. 
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a. Liquid Phase   
This project uses microfluidics to carry out the biological reactions on the device.  
Inherently, this approach requires that the samples being tested be in a liquid phase.  
Therefore, solid or gaseous samples cannot be analyzed using our device.  These phases 
cannot pass through the layers of the device, and the dried reagents on the layers will not 
be functionalized unless rehydrated with a liquid of near-neutral pH.  A possible solution 
to this issue is to dissolve samples in a simple liquid, such as water, and then add that 
solution to the device.  However, it is possible that with some samples this would be very 
difficult or impossible.  In such situations, our device would not be an appropriate 
solution for bacterial detection. 
b. Simple solutions 
A key step in our microfluidic device is the fluid flow throughout the device.  If 
the sample being tested is very complex, viscous, highly acidic or alkaline, or at extreme 
temperatures, then the functionality of our device may be constrained.  The fluid sample 
needs to be hydrophilic in order to flow through the cellulose channels, and it needs to be 
of a low viscosity in order to ensure fluid flow.  Complex solutions may hinder bacterial 
lysis and interfere with the reaction steps later in the device.  Extreme pH, salt balances, 
or temperature may affect the molecular structure of the DNA sequences and impair the 
functionality of the device.  The constraints that these factors place on the device may be 
mitigated since such extreme conditions may make bacterial survival unlikely as well. 
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CHAPTER 12:  ETHICAL CONSIDERATIONS 
I. Ethical Considerations 
The motto for Santa Clara’s School of Engineering is “Engineering with a 
mission”, which emphasizes the importance of using technical skills to benefit society.  
This focus demands a deep understanding of the ethical implications that accompany our 
project. The goal of our work is to address the unequal access to diagnostic medical 
devices between resource-rich and resource-limited areas.  By developing a low-cost 
microfluidic device that detects bacterial pathogens, we aim to breach the gap between 
life-saving technology and those who need it most. Through the lens of “A Framework 
for Thinking Ethically” provided by Santa Clara’s Markkula Center for Applied Ethics, 
we will analyze the ethical justification, embedded impact, and decision-making process 
involved in our project. 
  
 
Figure 11: Deaths Caused by Contaminated Water. World Health Organization’s 2002 report mapping 
the numbers of deaths worldwide caused by water/sanitation/hygiene (WSH) related diseases.[25] 
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II. Ethical Justification 
a. Utilitarian Justification 
In 2014, approximately 2,300 men, women, and children died every day as a 
result of unsanitary conditions.[26]   Similar deaths and illnesses could be avoided by 
rapid and reliable diagnostic tests to determine the safety of water, food, or other possible 
contaminated sources.  Quicker identification prevents prolonged exposure to bacterial 
pathogens and improved overall health for the individuals and communities at risk.  
Therefore, better diagnostic tools lead to more efficient health care, which saves lives and 
lowers medical costs for patients and professional health care services. 
b. Rights & Responsibilities Justification 
The United Nations’ Universal Declaration of Human Rights states in Article 3 
that “everyone has the right to life, liberty, and security of the person.”  Yet, the rights to 
life and basic health care are not being adequately met on a global scale.  Millions of 
people are made sick by contaminated water every year, and they often do not know the 
cause of the illness until it is too late. By providing quality diagnostic devices to 
communities in need, we can prevent pathogenic illness and save lives.   In doing this, we 
uphold our ethical responsibility to preserve the dignity of others and respect their rights 
to life and health. 
c. Justice & Fairness Justification 
750 million people are exposed to unsafe drinking water worldwide, with a vast 
majority of these people living in Africa and Asia.[27]  This limited accessibility leads to 
improper hygiene, ultimately creating a heightened risk of bacterial infection.  The 
unequal distribution of resources and basic health care disproportionately harms 
impoverished communities.  Our device can quickly detect the presence, identity, and 
quantity of pathogens, therefore contributing to medical care and illness prevention.  We 
aim to serve justice by providing fair and equal access to our device by making it low 
cost. Despite income inequalities and disparities in access to resources, our device 
promises high-quality diagnostics that are affordable to resource-limited areas.  
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d. Common Good Justification 
The old expression “an ounce of prevention is worth a pound of cure” holds 
especially true when dealing with health care. Healthier people cost healthcare systems 
less and contribute to society more. Therefore, society benefits as a whole when disease 
is reduced.  The targeted development of our device towards the marginalized not only 
helps the patients themselves, but also contributes to the common good of the community 
and society as a whole.  As referenced in the Santa Clara Engineering Handbook, 
bioethics expert Daniel Callahan emphasizes “replacing the current ‘ethic of individual 
rights’ with ‘an ethic of the common good’” in order to address the health care concerns 
in our modern world.  Our device serves the common good because the whole 
community benefits from the knowledge of what water, food, or environmental hazards 
to avoid. 
e. Virtue Justification 
The Biomedical Engineering Society sets forth a Code of Ethics that guides us to 
be good and just biomedical engineers.  It obligates us to use our knowledge to “enhance 
the safety, health, and welfare of public” as well as “strive by action, example, and 
influence to increase the competence, prestige, and honor of the biomedical engineering 
profession.”  This two-fold obligation not only compels us to be competent engineers, but 
also to form our character as leaders for good.  Adopting these virtues has compelled us 
to take on a project that improves the quality of life for the users of our device. 
III. Embedded Concerns & Decision-Making 
a. Utilitarian Embedded Concerns & Decision-Making 
To maximize the positive outcomes of this research, proper prioritization is 
necessary when allocating funds, time, and energy.  Optimizing the balance of these 
resources is crucial to accelerating the project and bringing it closer to the end user. 
Additionally, this project must be the best option for bacterial diagnostics in resource-
limited areas to be ethically justified.  If at any point a better technology arrives that 
outperforms this, then we must reevaluate the project and redirect it to maximally provide 
good. 
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b. Rights & Responsibilities Embedded Concerns & Decision-Making 
In addition to our responsibility to protect the basic human rights, we have 
responsibilities to address these concerns in the right way.  This includes our 
responsibility to maintain proper Health and Safety standards while employing 
environmentally conscious and sustainable practices.  Our device uses non-toxic 
chemicals, so it is safe to manufacture and produce for those involved in the fabrication 
process.  Furthermore, our device uses cellulose as the substrate, which is 
environmentally friendly, especially when compared to alternative plastic materials that 
often involve production methods hazardous to both workers and the environment.  After 
use, our devices can be cleanly burned, which eliminates waste without contributing to 
pollution. 
Ensuring proper and reliable use is another important aspect of our project.  We 
must be sure to properly test and validate the device to eliminate possible false-negatives 
and false-positives, as inaccurate readings may result in the end user being at risk.  
Accompanying this concern is the matter of usability.  If this device can practically be 
used by communities globally, it must be simple and durable to serve real-world 
applications.  Keeping these responsibilities in mind, we have taken the extra time to 
validate every step and develop the device before using it outside of the lab. 
c. Fairness and Justice Embedded Concerns & Decision-Making 
If the device is used fairly and justly, it can help marginalized groups have better 
control over their health and safety.  However, a concern is the proper distribution of this 
device to ensure that those in need have access to it.  By partnering with global non-profit 
organizations, such as the WHO, we aim to avoid the commoditization of the technology.  
At the same time, economic considerations must be taken to ensure continued production 
of the device and proper wages for the workers involved in this process.  Striking the 
balance between keeping the device affordable and respecting workers and the 
environment is a fine line, and partnering with the WHO or UN could help facilitate this 
balance. 
d. The Common Good Embedded Concerns & Decision-Making 
Serving the common good means contributing to the interlocking relationships of 
society.  As mentioned earlier, the diagnostic device must be made equally accessible for 
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the sake of justice, but the common good depends on that distribution as well.  Foreigners 
bringing in new technologies to communities may cause division within communities or 
complete rejection of the technology if the interaction is not conducted with respect.  
Also, it is possible some members of communities may seek to leverage access to this 
device for power or money, which would harm the common good even more.  Therefore, 
we must develop a model of distribution that respects local customs and values while still 
effectively reaching the targeted users.  This may come in the form of working with local 
health professionals who have both medical training and cultural ties to the communities.   
e. Virtue Approach Embedded Concerns & Decision-Making 
Charles Harris’ article “The Good Engineer: Giving Virtue Its Due in Engineering 
Ethics” addresses certain virtues that good engineers must have to address concerns in the 
field.  These include techno-social sensitivity, respect for nature, commitment to the 
public good, teamwork, and courage.  It is not enough for an engineer to create one 
ethical project, if he or she will then abandon those ethics in the sake of serving self-
interest.  Rather, a virtuous engineer is informed by society’s needs and acts in a way that 
serves the larger public good.  Additionally, any project undertaken will take into account 
the impact it will have on nature.  While these decisions may not always be easy, a 
virtuous engineer will never hesitate to take the hard road if it is the right road. 
IV. Conclusion 
We aim to address the global issue of illnesses caused by bacterial contamination 
through the development of a low-cost diagnostic device that could be used in resource-
limited areas globally (summarized in Table 6).  Identifying and quantifying 
contaminated sources can improve medical professional’s ability to treat illnesses, as well 
as prevent them. As a result, human dignity and right to life are upheld.  By producing the 
device at a low cost we preserve justice because all people will have equal access.  Proper 
manufacturing methods will protect the environment and respect the rights of workers. 
As the device is used, it will gradually lead to healthier communities, contributing to the 
common good.  If all these steps are taken with care and ethical leadership, then the 
greatest good will be done for the greatest number of people. 
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Table 6: Ethical Analysis. Breakdown of Ethical Framework for low-cost bacterial diagnostic device 
 
  
Justification Embedded Concerns Decision-Making 
Utilitarianism Better diagnostic 
tools contribute to 
preventing disease 
Alternative 
technologies may 
solve the issue 
better 
Stay informed about 
other research and 
technology to ensure 
that our device 
develops in a way that 
best meets healthcare 
needs 
Rights & 
Responsibilities 
We have 
responsibilities as 
engineers to protect 
human dignity and 
life 
1. Environmental 
Responsibility in 
manufacturing and 
disposal of device. 
2. Responsibility to 
create safe work 
environment for 
those who assemble 
the device 
1. Use cellulose as 
substrate because it is 
cost-effective, safe, and 
environmentally 
friendly. 
2. Construct ethical 
business model that 
respects rights of 
workers 
Justice & Fairness Our devices are 
affordable and 
therefore accessible 
to resource-limited 
communities 
Proper distribution 
and delivery of the 
device in resource-
limited settings 
Partner with global 
health organizations, 
such as the WHO or 
UN, to use their 
expertise in delivering 
the technology to those 
in need 
Common Good Healthy 
communities are 
more prosperous, 
and provide a better 
quality of life 
Proper use of device 
is required to 
actually help the 
end-users 
Design user-friendly 
device that is intuitive 
and practical for real-
world settings across 
cultures 
Virtue Good biomedical 
engineers 
demonstrate values 
that serve society, 
such as integrity and 
compassion 
Staying informed 
about society’s 
needs and 
consistently acting 
in an upright and 
ethical manner 
Collaborate with 
respected colleagues to 
further develop ethical 
character and decision-
making skills 
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CHAPTER 13: CONCLUSION 
 The research presented in this report is foundational for the future growth of this 
device. We were posed with the challenge of creating a bacterial detection device that 
could be used in the developing world because current methods fail to meet the WHO’s 
ASSURED criteria. With these criteria in mind, we have developed a platform to detect 
bacterial pathogens in solution. We demonstrated that an oligonucleotide sandwich assay 
is specific and sensitive enough to detect varying concentrations of Target 
oligonucleotide. We have fabricated a microfluidic chip that carefully controls the 
movement of fluids, allowing for future integration of the detection assay onto the device. 
The direction of this research is promising, as our current data has validated the device 
components to this point.  Future work built on the research we have complied thus far 
promises to achieve the goal of an ASSURED device for bacterial pathogen detection.  
Table 7: ASSURED Components of Device. Evaluation of our bacterial detection method against the 
WHO’s ASSURED criteria. 
A S S U R E D 
Affordable Sensitive Specific User- 
Friendly 
Rapid 
and 
Robust 
Equipment
Free 
Deliverable  
to End 
Users 
 
Paper-
based 
Can 
determine 
varying 
concentra-
tions of 
Target 
Oligonuc-
leotide 
sandwich 
assay to 
test for 
specific 
bacterial 
pathogens 
Autono-
mous 
microfluidic 
device 
Device 
materials 
Smart 
phone and 
applicati-
on used 
for 
analysis 
Durable, 
manufactu-
rabl device. 
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APPENDICES 
 
Oligonucleotide Sequences 
Sequence Name Nucleotide Sequence 5’-3’ Modifications 
Capture TTT GTC AAT GAG CAA AGG T 5’ Phosphate Addition 
Capture+Tag TTT GTC AAT GAG CAA AGG T 5’ Phosphate Addition, 
3’ C3 Fluorescein 
Target GGG GAG GAA GGG AGT AAA GTT 
AAT ACC TTT GCT CAT TGA C 
None 
Target+Tag GGG GAG GAA GGG AGT AAA GTT 
AAT ACC TTT GCT CAT TGA C 
5’ CAL Flour Red 610 
Detection TAC TCC CTT CCT CCC CTT TTT TTT 
TT 
3’ Thiol Addition 
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Cost Calculations: Material costs based on purchased  
Materials Cost per Device 
Cellulose $0.001 
Zirconia $1.00 
Capture DNA $0.60 
Detection DNA $0.50 
Gold Nanoparticles $1.40 
Wax $0.01 
Gold Enhancement $1.25 
ESTIMATED COST per 
DEVICE 
$4.76 
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Materials 
 
 
 
 
 
 
 
 
 
 
Material Item Number Vendor Location 
Gold Nanoparticles 741965 Sigma Aldrich St. Louis, MI 
Zirconia 771600 Sigma Aldrich St. Louis, MI 
Denhardt’s Solution 750018 Invitrogen Grand Island, NY 
DTT D9779 Sigma Aldrich St. Louis, MI 
Silver Enhancement 
(Solutions A & B) 
A: S5020 
B: S5145 
Sigma Aldrich St. Louis, MI 
Salmon Sperm DNA 15632011 Invitrogen Grand Island, NY 
Gold Enhancement 
Kit 
2115 Nanoprobes Yaphank, NY 
